← Atlas Theme · spans 1 topics
National priority voucher programs compress regulatory reviews of breakthrough drugs from months to weeks.
A new regulatory pathway designed to address critical national health targets and domestic supply chains allows select life-saving therapies to secure FDA approval in under two months.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
Revolution Medicines' Rasonque (Daraxonrasib) Wins Historic FDA Approval for Pancreatic Cancer Revolution Medicines' pancreatic cancer drug was cleared more than six months ahead of schedule under the rapid voucher review timeline.
Science & Health
FDA's Commissioner’s National Priority Voucher (CNPV) Pilot Program Accelerates Landmark Approvals to Under Two Months A newly created priority voucher pilot program is dramatically compressing federal drug review cycles for therapies targeting key national health and supply chain priorities.